A CHADS score is a point-based tool doctors use to estimate how likely a person with atrial fibrillation (an irregular heartbeat) is to have a stroke. The higher the score, the greater the risk, and the stronger the case for taking blood-thinning medication. The original version was called CHADS2, but it has since been updated to CHA2DS2-VASc, which is what most clinicians use today. A further revision called CHA2DS2-VA, which drops female sex as a factor, was adopted in 2024 European guidelines.
What the Letters Stand For
The name is a mnemonic. Each letter represents a health condition or characteristic that raises stroke risk in people with atrial fibrillation. In the widely used CHA2DS2-VASc version, the point breakdown looks like this:
- C: Congestive heart failure (1 point)
- H: Hypertension (1 point)
- A2: Age 75 or older (2 points)
- D: Diabetes (1 point)
- S2: Prior stroke or mini-stroke (2 points)
- V: Vascular disease, such as a previous heart attack or peripheral artery disease (1 point)
- A: Age 65 to 74 (1 point)
- Sc: Sex category, meaning female sex (1 point)
The maximum possible score is 9. The original CHADS2 score only included heart failure, hypertension, age 75 or older, diabetes, and prior stroke. The updated version added vascular disease, the 65-to-74 age range, and female sex to catch more people at meaningful risk.
How the Score Translates to Stroke Risk
Each point on the scale corresponds to a higher annual chance of having a stroke. For people with atrial fibrillation, a score of 1 carries roughly a 1.3% per year stroke risk, while a score of 2 raises it to about 2.2% per year. At a score of 5 or above, the one-year risk climbs to around 3.5%. These numbers may sound small in percentage terms, but strokes caused by atrial fibrillation tend to be severe, so even modest-sounding percentages translate into real danger over several years.
Looking at longer time horizons makes the risk clearer. Over 10 years, someone with a score of 0 or 1 faces about a 1.2% cumulative chance of ischemic stroke, while someone scoring 5 or higher faces roughly a 7% chance over the same period.
What the Score Means for Treatment
The main reason doctors calculate this score is to decide whether blood-thinning medication (anticoagulation) is worth the trade-off. Blood thinners reduce stroke risk significantly, but they also increase the chance of bleeding. The 2023 American College of Cardiology and American Heart Association guidelines frame the decision around three risk tiers: low (under about 1% per year), intermediate (1 to 2% per year), and high (over 2% per year).
In practice, a score of 2 or higher in men (or 3 or higher in women, since the female sex point doesn’t indicate risk on its own) is where guidelines strongly recommend anticoagulation. A score of 1 in men or 2 in women falls into a gray zone where the recommendation is weaker, and the decision often involves a conversation between you and your doctor about your comfort with the risks on both sides. A score of 0 in men or 1 in women (where the only point comes from being female) generally means the stroke risk is low enough that blood thinners aren’t recommended.
The threshold that tips the balance is roughly a 2% annual stroke risk. At that level, the benefit of preventing a stroke far exceeds the risk of a serious bleed.
The 2024 Update: CHA2DS2-VA
The 2024 European Society of Cardiology guidelines introduced a slightly revised version called CHA2DS2-VA, which removes female sex from the scoring entirely. The reasoning is that being female, on its own, doesn’t independently drive stroke risk enough to warrant its own point. Under this newer system, anticoagulation is recommended for a score of 2 or higher regardless of sex, and can be considered at a score of 1.
This change matters most for women. One study found that after recalibrating to the new score, about 14% of women who had already experienced an ischemic stroke fell below the treatment threshold, meaning the updated score would not have flagged them for blood thinners. Women were nearly six times more likely than men to drop below the anticoagulation cutoff after this recalibration. This is still being debated, and different countries and medical systems may adopt the change at different speeds.
Balancing Stroke Risk With Bleeding Risk
The CHADS score only addresses one side of the equation: stroke risk. Doctors typically pair it with a separate tool called HAS-BLED, which estimates your one-year risk of a major bleed while on blood thinners. Factors in HAS-BLED include uncontrolled high blood pressure, kidney or liver problems, history of bleeding, and alcohol use.
A high HAS-BLED score doesn’t automatically mean you should skip blood thinners. Instead, it flags that your bleeding risk factors need to be managed more carefully. Clinicians weigh both scores together, looking at the balance between preventing a potentially devastating stroke and avoiding a serious bleed. In most cases where both scores are elevated, the stroke prevention benefit still wins out, but the decision becomes more nuanced and personalized.
Who the Score Applies To
The CHA2DS2-VASc score was designed specifically for people with nonvalvular atrial fibrillation, meaning atrial fibrillation that isn’t caused by a mechanical heart valve or significant mitral valve disease. People with valvular heart disease are typically excluded from studies that validate the score, and they usually need anticoagulation regardless of their point total.
The score is a moderately accurate predictor of stroke. Validation studies show it performs in the moderate range statistically, meaning it’s useful for sorting people into risk categories but isn’t a perfect crystal ball. It works best as a starting point for conversation, not as a final verdict. Your doctor may factor in additional details about your health that the score doesn’t capture, like how well your atrial fibrillation is controlled or whether you have other conditions that affect clotting.